NCT04700319View on ClinicalTrials.gov

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

May 1, 2021

Study Completion Date

June 1, 2021

Conditions
CAR
Interventions
DRUG

CD19/CD20 CAR-T cell infusion

CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once

Trial Locations (1)

230000

RECRUITING

Anhui Provincial Hospital, Hefei

Sponsors
All Listed Sponsors
collaborator

Anhui Provincial Hospital

OTHER_GOV

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY

NCT04700319 - CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies | Biotech Hunter | Biotech Hunter